ERBB2 and breast cancer: For instance, after bladder resection, ctDNA analysis correctly identified all patients with recurrent metastases during disease monitoring.242 In HR-positive/HER2-negative BC patients, ctDNA positivity is associated with a reduced rate of distant recurrence-free survival, whereas ctDNA negativity is associated with improved prognosis.243 Therefore, monitoring ctDNA may potentially replace standard care tissue biopsies based on DNA biomarker assessment, potentially improving clinical management in predicting the future recurrence of many cancers.244